INVESTIGATION NOTICE: Cerevel shareholders urged to request information on BFA Law’s investigation into $45K merger offer

New York, New York–(Newsfile Corp. – May 31, 2024) – Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and AbbVie, Inc. If you have invested in Cerevel Therapeutics, you can obtain more information at: https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation.

To view an expanded version of this graphic, please visit:
https://images.newsfilecorp.com/files/10531/211200_613d5ffd64b38bdc_001full.jpg

Claim details:

On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all of Cerevel’s outstanding shares for $45.00 per share in cash. The transaction values ​​Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in mid-2024.

BFA is currently investigating the privatization transaction and believes that Cerevel Therapeutics’ board of directors was involved in conflicts of interest, engaged in an unfair process, and agreed to an unfair payout to shareholders. If you are already a shareholder, you are asked to submit your information to learn more about your rights.

Submit your information here: https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation.

Next Steps:

If you currently own shares of Cerevel Therapeutics, you may have legal options available to you and be required to provide your information to the company.

All representation is on a contingency basis. There are no costs for youShareholders will not be responsible for any court or litigation costs. The Company will seek court approval for any fees and costs.

To speak with an attorney and get more information, visit:

https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation

Or contact us:

Ross Shikowitz
[email protected]
212-789-2303

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in class actions and shareholder derivative litigation. It was named a Top 5 Plaintiffs Firm for 2023 by ISS SCAS and its lawyers have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Recent notable successes include BFA recovering over $900 million in value from the board of Tesla, Inc. (subject to court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation

Attorney advertising. Past results do not guarantee future results.

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/211200